Remdesivir (GS-5734) for COVID-19 Treatment: Past and Recent Updates

Author(s): Santhosh Arul, Haripriya Dayalan*

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses

Volume 2 , Issue 8 , 2021


Article ID: e260721189168
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: SARS-CoV-2 is a pandemic now, and several measures have been taken by countries to prevent, control, and treat the disease. WHO has been working meticulously and has been providing up to date information and statistics on incidences and death. Several broad- -spectrum anti-viral drugs are available and have been used in the past to fight against the viral outbreak. Recently remdesivir, an experimental prodrug from Gilead Sciences, has been found to be a potential drug to be used as a therapy to treat COVID-19.

Objective: Here, we have reviewed several previous findings from the literature and present an up to date information on remdesivir.

Result: Remdesivir was initially invented for use against Ebola virus treatment and has proved effective against different strains of Ebola, Nipah, and other strains of coronaviruses. Clinical trials with remdesivir for COVID-19 patients have begun, and several off label use of remdesivir have been reported recently. Currently, the drug seems to have an effect against the SARS-CoV-2 virus, with side effects among a few patients. Although the results are not conclusive, they are partly promising. This review provides past and recent updates on the use of remdesivir.

Conclusion: From the review, we conclude that the drug remdesivir is known to exhibit its mechanism of action by terminating the RNA synthesis, and it is a potential drug against the novel coronavirus.

Keywords: SARS-CoV-2, coronavirus, remdesivir, clinical trial, RNA synthesis, mechanism, COVID-19.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 2
ISSUE: 8
Year: 2021
Published on: 15 December, 2020
Article ID: e260721189168
Pages: 6
DOI: 10.2174/2666796701999201216102250

Article Metrics

PDF: 11